Literature DB >> 21762720

Systems biology of JAK-STAT signalling in human malignancies.

Julio Vera1, Katja Rateitschak, Falko Lange, Christina Kossow, Olaf Wolkenhauer, Robert Jaster.   

Abstract

Originally implicated in the regulation of survival, proliferation and differentiation of haematopoietic cells, the JAK-STAT pathway has also been linked to developmental processes, growth control and maintenance of homeostasis in a variety of other cells and tissues. Although it remains a complex system, its relative simplicity and the availability of molecular data makes it particularly attractive for modelling approaches. In this review, we will focus on JAK-STAT signalling in the context of cancer and present efforts to investigate signalling dynamics with the help of mathematical models. We describe the modelling workflow that realises a systems biology approach and give an example for interferon-γ signalling in pancreatic stellate cells.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762720     DOI: 10.1016/j.pbiomolbio.2011.06.013

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  25 in total

1.  Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.

Authors:  Ying-Na Bao; Xue Cao; Dong-Hua Luo; Rui Sun; Li-Xia Peng; Lin Wang; Yong-Pan Yan; Li-Sheng Zheng; Ping Xie; Yun Cao; Ying-Ying Liang; Fang-Jing Zheng; Bi-Jun Huang; Yan-Qun Xiang; Xing Lv; Qiu-Yan Chen; Ming-Yuan Chen; Pei-Yu Huang; Ling Guo; Hai-Qiang Mai; Xiang Guo; Yi-Xin Zeng; Chao-Nan Qian
Journal:  Cell Cycle       Date:  2014-04-24       Impact factor: 4.534

2.  MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway.

Authors:  Xilong Wang; Wenxiu Qiu; Guoqiang Zhang; Shujian Xu; Qiang Gao; Zhenlin Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.

Authors:  Yanfen Fang; Like Zhong; Meihua Lin; Xinglu Zhou; Hui Jing; Meidan Ying; Peihua Luo; Bo Yang; Qiaojun He
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

4.  Systems biology of fungal infection.

Authors:  Fabian Horn; Thorsten Heinekamp; Olaf Kniemeyer; Johannes Pollmächer; Vito Valiante; Axel A Brakhage
Journal:  Front Microbiol       Date:  2012-04-02       Impact factor: 5.640

5.  Janus kinase 2 polymorphisms are associated with risk in patients with gastric cancer in a Chinese population.

Authors:  Li Yang; Dongxiao Liu; Song Liang; Renhua Guo; Zhihong Zhang; Hao Xu; Chao Yang; Yi Zhu
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

6.  Autworks: a cross-disease network biology application for Autism and related disorders.

Authors:  Tristan H Nelson; Jae-Yoon Jung; Todd F Deluca; Byron K Hinebaugh; Kristian Che St Gabriel; Dennis P Wall
Journal:  BMC Med Genomics       Date:  2012-11-28       Impact factor: 3.063

7.  The STAT3-Ser/Hes3 signaling axis: an emerging regulator of endogenous regeneration and cancer growth.

Authors:  Steven W Poser; Deric M Park; Andreas Androutsellis-Theotokis
Journal:  Front Physiol       Date:  2013-10-01       Impact factor: 4.566

8.  Secretome identification of immune cell factors mediating metastatic cell homing.

Authors:  Brian A Aguado; Jia J Wu; Samira M Azarin; Dhaval Nanavati; Shreyas S Rao; Grace G Bushnell; Chaitanya B Medicherla; Lonnie D Shea
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

Review 9.  Computational models of the JAK1/2-STAT1 signaling.

Authors:  Anna Gambin; Agata Charzyńska; Aleksandra Ellert-Miklaszewska; Mikołaj Rybiński
Journal:  JAKSTAT       Date:  2013-04-15

10.  Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells.

Authors:  Ji Hoon Jung; Tae-Rin Kwon; Soo-Jin Jeong; Eun-Ok Kim; Eun Jung Sohn; Miyong Yun; Sung-Hoon Kim
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-26       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.